U.S. markets closed

DURECT Corporation (DRRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.6851+0.0364 (+5.61%)
At close: 04:00PM EDT
0.7000 +0.01 (+2.17%)
After hours: 04:05PM EDT

DURECT Corporation

10260 Bubb Road
Cupertino, CA 95014-4166
United States
408 777 1417

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees78

Key Executives

NameTitlePayExercisedYear Born
Dr. James E. Brown D.V.M.Co-Founder, CEO, Pres & Director859.68kN/A1957
Ms. Judy R. JoiceSr. VP of Operations & Corp. Quality Assurance436.99k102.25k1957
Dr. Norman L. Sussman M.D.Chief Medical Officer570.32kN/A1953
Mr. Timothy M. PappChief Financial OfficerN/AN/AN/A
Ms. Jian Li M.B.A.Interim Principal Accounting Officer, Sr. VP of Fin., Corp. Controller & Sec.N/AN/A1970
Dr. Andrew R. Miksztal Ph.D.VP of Pharmaceutical R&D and Principal ScientistN/AN/AN/A
Mr. Steve Helmer J.D.VP & Chief Patent CounselN/AN/AN/A
Dr. WeiQi LinExec. VP of R&D and Principal ScientistN/AN/AN/A
Dr. Su Il Yum Ph.D.Exec. OfficerN/AN/A1939
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Corporate Governance

DURECT Corporation’s ISS Governance QualityScore as of July 31, 2022 is 6. The pillar scores are Audit: 5; Board: 4; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.